• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

作者信息

Heerspink Hiddo J L, Coresh Josef, Gansevoort Ron T, Inker Lesley A

机构信息

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

出版信息

Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4.

DOI:10.1016/S2213-8587(19)30080-4
PMID:31003622
Abstract
摘要

相似文献

1
Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.蛋白尿变化作为慢性肾脏病替代终点——作者回复
Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4.
2
Change in albuminuria as a surrogate endpoint in chronic kidney disease.蛋白尿变化作为慢性肾脏病替代终点指标
Lancet Diabetes Endocrinol. 2019 May;7(5):335. doi: 10.1016/S2213-8587(19)30089-0.
3
Change in albuminuria as a surrogate endpoint in chronic kidney disease.蛋白尿变化作为慢性肾脏病的替代终点
Lancet Diabetes Endocrinol. 2019 May;7(5):335-336. doi: 10.1016/S2213-8587(19)30085-3.
4
Urinary biomarkers of tubular injury in chronic kidney disease.慢性肾脏病肾小管损伤的尿生物标志物。
Kidney Int. 2017 Jan;91(1):21-23. doi: 10.1016/j.kint.2016.10.003.
5
Albuminuria in Childhood is a Risk Factor for Chronic Kidney Disease and End-Stage Renal Disease.儿童期蛋白尿是慢性肾脏病和终末期肾病的危险因素。
Pediatr Neonatol. 2016 Aug;57(4):263-4. doi: 10.1016/j.pedneo.2015.05.005. Epub 2016 Jun 11.
6
Authors' Reply.作者回复。
J Am Soc Nephrol. 2020 Feb;31(2):448-449. doi: 10.1681/ASN.2019111188. Epub 2019 Dec 23.
7
Working towards novel albuminuria endpoints in chronic kidney disease.致力于慢性肾脏疾病中新型蛋白尿终点的研究。
Lancet Diabetes Endocrinol. 2019 Feb;7(2):80-82. doi: 10.1016/S2213-8587(18)30352-8. Epub 2019 Jan 8.
8
Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.慢性肾脏病进展临床试验中的替代终点：从单一风险标志物反应评分转向多风险标志物反应评分。
Curr Opin Nephrol Hypertens. 2015 Nov;24(6):492-7. doi: 10.1097/MNH.0000000000000159.
9
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.非白蛋白尿性慢性肾脏病向终末期肾病进展的风险：CRIC（慢性肾功能不全队列）研究。
Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18.
10
Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.慢性肾脏病患者心力衰竭的危险因素：CRIC（慢性肾功能不全队列）研究
J Am Heart Assoc. 2017 May 17;6(5):e005336. doi: 10.1161/JAHA.116.005336.

引用本文的文献

1
Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease-A practical update for clinicians.蛋白尿检测的进展：肾脏和心血管疾病检测、预后及监测的关键生物标志物——临床医生实用更新
Diabetes Obes Metab. 2025 Sep;27 Suppl 8(Suppl 8):15-33. doi: 10.1111/dom.16359. Epub 2025 Mar 26.
2
Mitochondria in Diabetic Kidney Disease.糖尿病肾病中的线粒体。
Cells. 2021 Oct 29;10(11):2945. doi: 10.3390/cells10112945.
3
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial.
卡格列净可早期降低蛋白尿，并预测肾脏和心血管结局：来自 CREDENCE 试验的分析。
J Am Soc Nephrol. 2020 Dec;31(12):2925-2936. doi: 10.1681/ASN.2020050723. Epub 2020 Sep 30.
4
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.每周一次给予艾塞那肽可降低伴有白蛋白尿升高的 2 型糖尿病患者的尿白蛋白排泄量：随机对照临床试验的汇总分析。
Diabetes Obes Metab. 2020 Sep;22(9):1556-1566. doi: 10.1111/dom.14067. Epub 2020 May 29.
5
The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.糖尿病肾病的新生物学：机制与治疗意义。
Endocr Rev. 2020 Apr 1;41(2):202-31. doi: 10.1210/endrev/bnz010.
6
The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.肠促胰岛素途径作为糖尿病肾病的治疗靶点：聚焦于胰高血糖素样肽-1受体激动剂的临床研究
Ther Adv Endocrinol Metab. 2019 Jul 24;10:2042018819865398. doi: 10.1177/2042018819865398. eCollection 2019.